Varma Mutual Pension Insurance Co Sells 2,112 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Varma Mutual Pension Insurance Co cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,088 shares of the biopharmaceutical company’s stock after selling 2,112 shares during the period. Varma Mutual Pension Insurance Co’s holdings in Regeneron Pharmaceuticals were worth $21,113,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Triasima Portfolio Management inc. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $1,780,000. Koss Olinger Consulting LLC bought a new position in Regeneron Pharmaceuticals in the second quarter worth approximately $346,000. Caprock Group LLC increased its holdings in Regeneron Pharmaceuticals by 60.2% during the 2nd quarter. Caprock Group LLC now owns 1,386 shares of the biopharmaceutical company’s stock worth $1,457,000 after purchasing an additional 521 shares during the period. Certuity LLC raised its position in Regeneron Pharmaceuticals by 37.9% during the 2nd quarter. Certuity LLC now owns 1,718 shares of the biopharmaceutical company’s stock valued at $1,805,000 after purchasing an additional 472 shares in the last quarter. Finally, Custom Index Systems LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 36.7% in the 2nd quarter. Custom Index Systems LLC now owns 328 shares of the biopharmaceutical company’s stock worth $345,000 after buying an additional 88 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded down $19.06 during mid-day trading on Friday, reaching $1,131.50. 616,625 shares of the company traded hands, compared to its average volume of 468,461. The firm’s fifty day moving average is $1,113.10 and its two-hundred day moving average is $1,020.18. The company has a market capitalization of $124.68 billion, a price-to-earnings ratio of 33.43, a price-to-earnings-growth ratio of 3.13 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $769.19 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same period in the previous year, the company earned $8.79 earnings per share. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Barclays raised their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Evercore ISI began coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price target for the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $1,250.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday. JPMorgan Chase & Co. boosted their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Finally, Canaccord Genuity Group restated a “buy” rating and set a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,108.95.

Insider Activity

In other news, CEO Leonard S. Schleifer sold 9,064 shares of the company’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $1,015.43, for a total value of $9,203,857.52. Following the sale, the chief executive officer now directly owns 55,134 shares of the company’s stock, valued at approximately $55,984,717.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Leonard S. Schleifer sold 9,064 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $1,015.43, for a total value of $9,203,857.52. Following the transaction, the chief executive officer now owns 55,134 shares of the company’s stock, valued at $55,984,717.62. The disclosure for this sale can be found here. Over the last three months, insiders have sold 20,625 shares of company stock valued at $22,298,963. Company insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.